Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells

S. G M Piccirillo, B. A. Reynolds, N. Zanetti, G. Lamorte, E. Binda, G. Broggi, H. Brem, A. Olivi, F. Dimeco, A. L. Vescovi

Research output: Contribution to journalArticle

864 Citations (Scopus)

Abstract

Transformed, oncogenic precursors, possessing both defining neural-stem-cell properties and the ability to initiate intracerebral tumours, have been identified in human brain cancers. Here we report that bone morphogenetic proteins (BMPs), amongst which BMP4 elicits the strongest effect, trigger a significant reduction in the stem-like, tumour-initiating precursors of human glioblastomas (GBMs). Transient in vitro exposure to BMP4 abolishes the capacity of transplanted GBM cells to establish intracerebral GBMs. Most importantly, in vivo delivery of BMP4 effectively blocks the tumour growth and associated mortality that occur in 100% of mice after intracerebral grafting of human GBM cells. We demonstrate that BMPs activate their cognate receptors (BMPRs) and trigger the Smad signalling cascade in cells isolated from human glioblastomas (GBMs). This is followed by a reduction in proliferation, and increased expression of markers of neural differentiation, with no effect on cell viability. The concomitant reduction in clonogenic ability, in the size of the CD133+ population and in the growth kinetics of GBM cells indicates that BMP4 reduces the tumour-initiating cell pool of GBMs. These findings show that the BMP-BMPR signalling system - which controls the activity of normal brain stem cells - may also act as a key inhibitory regulator of tumour-initiating, stem-like cells from GBMs and the results also identify BMP4 as a novel, non-cytotoxic therapeutic effector, which may be used to prevent growth and recurrence of GBMs in humans.

Original languageEnglish (US)
Pages (from-to)761-765
Number of pages5
JournalNature
Volume444
Issue number7120
DOIs
StatePublished - Dec 7 2006

Fingerprint

Bone Morphogenetic Proteins
Neoplastic Stem Cells
Glioblastoma
Brain Neoplasms
Neoplasms
Stem Cells
Neural Stem Cells
Population Growth
Differentiation Antigens
Growth
Brain Stem
Cell Survival
Recurrence
Mortality

ASJC Scopus subject areas

  • Medicine(all)
  • General

Cite this

Piccirillo, S. G. M., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., ... Vescovi, A. L. (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature, 444(7120), 761-765. https://doi.org/10.1038/nature05349

Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. / Piccirillo, S. G M; Reynolds, B. A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F.; Vescovi, A. L.

In: Nature, Vol. 444, No. 7120, 07.12.2006, p. 761-765.

Research output: Contribution to journalArticle

Piccirillo, SGM, Reynolds, BA, Zanetti, N, Lamorte, G, Binda, E, Broggi, G, Brem, H, Olivi, A, Dimeco, F & Vescovi, AL 2006, 'Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells', Nature, vol. 444, no. 7120, pp. 761-765. https://doi.org/10.1038/nature05349
Piccirillo SGM, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006 Dec 7;444(7120):761-765. https://doi.org/10.1038/nature05349
Piccirillo, S. G M ; Reynolds, B. A. ; Zanetti, N. ; Lamorte, G. ; Binda, E. ; Broggi, G. ; Brem, H. ; Olivi, A. ; Dimeco, F. ; Vescovi, A. L. / Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. In: Nature. 2006 ; Vol. 444, No. 7120. pp. 761-765.
@article{eb156f121c7b4eecb5f2a6d2f3a090fd,
title = "Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells",
abstract = "Transformed, oncogenic precursors, possessing both defining neural-stem-cell properties and the ability to initiate intracerebral tumours, have been identified in human brain cancers. Here we report that bone morphogenetic proteins (BMPs), amongst which BMP4 elicits the strongest effect, trigger a significant reduction in the stem-like, tumour-initiating precursors of human glioblastomas (GBMs). Transient in vitro exposure to BMP4 abolishes the capacity of transplanted GBM cells to establish intracerebral GBMs. Most importantly, in vivo delivery of BMP4 effectively blocks the tumour growth and associated mortality that occur in 100{\%} of mice after intracerebral grafting of human GBM cells. We demonstrate that BMPs activate their cognate receptors (BMPRs) and trigger the Smad signalling cascade in cells isolated from human glioblastomas (GBMs). This is followed by a reduction in proliferation, and increased expression of markers of neural differentiation, with no effect on cell viability. The concomitant reduction in clonogenic ability, in the size of the CD133+ population and in the growth kinetics of GBM cells indicates that BMP4 reduces the tumour-initiating cell pool of GBMs. These findings show that the BMP-BMPR signalling system - which controls the activity of normal brain stem cells - may also act as a key inhibitory regulator of tumour-initiating, stem-like cells from GBMs and the results also identify BMP4 as a novel, non-cytotoxic therapeutic effector, which may be used to prevent growth and recurrence of GBMs in humans.",
author = "Piccirillo, {S. G M} and Reynolds, {B. A.} and N. Zanetti and G. Lamorte and E. Binda and G. Broggi and H. Brem and A. Olivi and F. Dimeco and Vescovi, {A. L.}",
year = "2006",
month = "12",
day = "7",
doi = "10.1038/nature05349",
language = "English (US)",
volume = "444",
pages = "761--765",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7120",

}

TY - JOUR

T1 - Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells

AU - Piccirillo, S. G M

AU - Reynolds, B. A.

AU - Zanetti, N.

AU - Lamorte, G.

AU - Binda, E.

AU - Broggi, G.

AU - Brem, H.

AU - Olivi, A.

AU - Dimeco, F.

AU - Vescovi, A. L.

PY - 2006/12/7

Y1 - 2006/12/7

N2 - Transformed, oncogenic precursors, possessing both defining neural-stem-cell properties and the ability to initiate intracerebral tumours, have been identified in human brain cancers. Here we report that bone morphogenetic proteins (BMPs), amongst which BMP4 elicits the strongest effect, trigger a significant reduction in the stem-like, tumour-initiating precursors of human glioblastomas (GBMs). Transient in vitro exposure to BMP4 abolishes the capacity of transplanted GBM cells to establish intracerebral GBMs. Most importantly, in vivo delivery of BMP4 effectively blocks the tumour growth and associated mortality that occur in 100% of mice after intracerebral grafting of human GBM cells. We demonstrate that BMPs activate their cognate receptors (BMPRs) and trigger the Smad signalling cascade in cells isolated from human glioblastomas (GBMs). This is followed by a reduction in proliferation, and increased expression of markers of neural differentiation, with no effect on cell viability. The concomitant reduction in clonogenic ability, in the size of the CD133+ population and in the growth kinetics of GBM cells indicates that BMP4 reduces the tumour-initiating cell pool of GBMs. These findings show that the BMP-BMPR signalling system - which controls the activity of normal brain stem cells - may also act as a key inhibitory regulator of tumour-initiating, stem-like cells from GBMs and the results also identify BMP4 as a novel, non-cytotoxic therapeutic effector, which may be used to prevent growth and recurrence of GBMs in humans.

AB - Transformed, oncogenic precursors, possessing both defining neural-stem-cell properties and the ability to initiate intracerebral tumours, have been identified in human brain cancers. Here we report that bone morphogenetic proteins (BMPs), amongst which BMP4 elicits the strongest effect, trigger a significant reduction in the stem-like, tumour-initiating precursors of human glioblastomas (GBMs). Transient in vitro exposure to BMP4 abolishes the capacity of transplanted GBM cells to establish intracerebral GBMs. Most importantly, in vivo delivery of BMP4 effectively blocks the tumour growth and associated mortality that occur in 100% of mice after intracerebral grafting of human GBM cells. We demonstrate that BMPs activate their cognate receptors (BMPRs) and trigger the Smad signalling cascade in cells isolated from human glioblastomas (GBMs). This is followed by a reduction in proliferation, and increased expression of markers of neural differentiation, with no effect on cell viability. The concomitant reduction in clonogenic ability, in the size of the CD133+ population and in the growth kinetics of GBM cells indicates that BMP4 reduces the tumour-initiating cell pool of GBMs. These findings show that the BMP-BMPR signalling system - which controls the activity of normal brain stem cells - may also act as a key inhibitory regulator of tumour-initiating, stem-like cells from GBMs and the results also identify BMP4 as a novel, non-cytotoxic therapeutic effector, which may be used to prevent growth and recurrence of GBMs in humans.

UR - http://www.scopus.com/inward/record.url?scp=33845610993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845610993&partnerID=8YFLogxK

U2 - 10.1038/nature05349

DO - 10.1038/nature05349

M3 - Article

C2 - 17151667

AN - SCOPUS:33845610993

VL - 444

SP - 761

EP - 765

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7120

ER -